Wave Life Sciences Ltd. (WVE) on Monday reported positive interim results from its first-in-human INLIGHT trial evaluating WVE-007 for obesity, sending the company's shares up more than 70% in pre-market trading.
Following a single 240 mg dose, WVE-007 improved body composition at three months versus baseline, with a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass, while no significant changes were observed in the placebo group.
The treatment was generally safe and well tolerated, with only mild adverse events and no meaningful changes in lab measurements, including lipid profiles or liver function tests.
Wave Life Sciences plans Phase 2 trials of WVE-007 both as monotherapy and as an add-on to incretins in people with higher BMI and related comorbidities, and as maintenance therapy post-incretin treatment.
Additional data updates, including six-month follow-up for the 240 mg cohort and three-month follow-up for the 400 mg cohort, are expected in the first quarter of 2026.
Wave Life Sciences stock closed Friday's trading at $7.49, down 1.71%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.